导语：华夏李俊偏被动量化，适合新手和保守型基民；财通金梓才和永赢李文宾更激进，追求高回报但 波动大；诺安刘慧影和广发刘格菘更注重平衡。 二、金梓才（财通基金，财通成长优选） 金梓才从业逾10年，专注科技成长股投资。他管理的基金如财通成长优选混合，2025年回报率约 59.13%，位居同类前列，重仓AI算力股如中际旭创和新易盛。 特点：行业轮动高手，强调AI产业周期研判，2025年精准布局海外算力传导至A股的机会。投资风格偏 成长，集中持仓（前十大占比超70%），但通过动态调整分散风险。相比纯指数跟踪，他更注重Alpha挖 掘，如提前配置人形机器人概念股。风险方面，波动较大，适合高风险偏好投资者。 三、李文宾（永赢基金，永赢科技驱动） 作者：张清 2025年，人工智能（AI）作为A股市场的最大热点，可以说是带动了整个行情的进行。所谓时势造英 雄，这期间，一批优秀的基金经理通过深度产业研判、量化模型和成长价值平衡等策略，纷纷实现超额 回报。本文选取五位在人工智能（AI）主题基金领域表现突出的基金经理，包括华夏人工智能AI ETF （515070）的基金经理李俊，以及金梓才、李文宾、刘格菘和刘慧影。他们管理的基金在 ...

Group 1 - The core trend observed in the second quarter of 2025 is that many prominent fund managers are increasing their positions in the innovative drug sector, indicating a growing interest in this area [1] - Yongying Fund's Gao Nan reported that the total scale of the funds he manages reached 15.326 billion yuan, a significant increase of nearly 3.5 billion yuan compared to the end of the first quarter [2] - Several funds managed by Gao Nan achieved net value growth exceeding 10%, ranking among the top in their category, showcasing a dual increase in performance and scale [2] Group 2 - The top ten holdings of Gao Nan's flagship fund, Yongying Ruixin, saw significant adjustments, with new additions from the communication equipment sector and innovative drug companies [3] - Major new holdings include companies like ZTE and Innovent Biologics, while positions in BYD and Ninebot were exited [3][4] - The three main investment directions for Gao Nan's funds are communication (TMT), innovative drugs, and light manufacturing, reflecting a clear structural adjustment in response to market themes [4] Group 3 - Gao Nan emphasizes stock selection based on company growth potential and earnings realization, aiming to reduce industry concentration while capturing growth opportunities [5] - The Yongying Technology Driven Fund plans to increase exposure to the artificial intelligence supply chain and reallocate in defense and biomedicine sectors [5] - Gao Nan expresses cautious optimism for the second half of the year, noting improved liquidity conditions and a strong financial risk prevention system established by the government [5] Group 4 - Ruiyuan Fund's Fu Pengbo also significantly increased allocations to the pharmaceutical sector, particularly in innovative drugs, during the second quarter [6] - The Ruiyuan Growth Value Mixed Fund reached a scale of 18.666 billion yuan, with a net value growth rate of 5.80%, outperforming its benchmark by 4.13 percentage points [6][7] - Fu Pengbo's portfolio is heavily weighted towards electronics, internet technology, precision manufacturing, and pharmaceuticals, with a stock position exceeding 92% [7] Group 5 - Fu Pengbo's strategy involves increasing holdings in the pharmaceutical sector, covering innovative drugs and traditional medicine benefiting from AI, while reducing exposure to traditional energy companies [10] - He plans to closely monitor mid-year reports from listed companies and seek industries and companies with rising prosperity [11] - Both Gao Nan and Fu Pengbo share a focus on innovative drugs, providing investors with a reference point for market trends and industry movements [11]

Core Viewpoint - The article discusses the investment strategy and positioning of Yongying Fund's "Intelligent Selection Series," particularly focusing on the advanced manufacturing sector and robotics, emphasizing the importance of recognizing value and understanding risks before making investment decisions [1]. Group 1: Product Positioning and Strategy - Yongying Fund is optimistic about new production capabilities and has developed the "Intelligent Selection Series" to align with national strategic directions, supporting real enterprises while providing investors with tools to seize investment opportunities in high-potential sectors [2][3]. - The "Intelligent Selection Series" combines active research and quantitative investment methods, focusing on "unicorn" industries that are scarce and have significant growth potential [2][4]. Group 2: Historical Context and Development - The company began laying out this product series in 2022, responding to market downturns and aiming for a counter-cyclical investment strategy, launching several products including the popular Yongying Semiconductor Industry Intelligent Selection and Yongying Low Carbon Environmental Protection Intelligent Selection [3][4]. - The advanced manufacturing product was quietly launched in May 2023, reflecting the company's long-term commitment to sectors like robotics and low-altitude economy as they mature [3]. Group 3: Investment Philosophy - The company believes in the unique advantages of capital markets in supporting technological innovation and aims to guide funds towards key technological enterprises, enhancing the integration of technology and industry [4][5]. - The "Intelligent Selection Series" is designed as a tool for investors to capture industry trends, with a focus on specific high-growth sectors, while other technology growth products maintain a more balanced risk distribution [9]. Group 4: Market Dynamics and Recommendations - The company acknowledges the volatility associated with high-growth sectors like advanced manufacturing but emphasizes the long-term growth potential in these areas, encouraging investors to adopt a rational approach rather than chasing short-term gains [10][11]. - The fund manager recommends a systematic investment approach, such as dollar-cost averaging, to mitigate short-term market fluctuations and to align with the long-term growth of the technology sector [12]. Group 5: Future Directions - Yongying Fund plans to continue expanding the "Intelligent Selection Series," focusing on emerging technologies and industries, while enhancing its investment management capabilities to help investors capture significant opportunities in these sectors [15].